PepGen (PEPG) to Release Earnings on Thursday

PepGen (NASDAQ:PEPG) is expected to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 6, 2025 at 7:00 AM ET.

PepGen (NASDAQ:PEPG) last announced its earnings results on Thursday, August 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.15. On average, analysts expect PepGen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PepGen Stock Down 9.4%

Shares of NASDAQ PEPG opened at $4.51 on Thursday. PepGen has a 52-week low of $0.88 and a 52-week high of $7.50. The business has a 50-day moving average price of $3.20 and a 200 day moving average price of $2.02. The stock has a market cap of $147.93 million, a PE ratio of -1.52 and a beta of 1.96.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Wedbush increased their price objective on PepGen from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th. HC Wainwright increased their price objective on PepGen from $12.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday. Stifel Nicolaus increased their price objective on PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PepGen in a research report on Wednesday, October 8th. Finally, Guggenheim reaffirmed a “buy” rating and set a $6.00 price objective on shares of PepGen in a research report on Wednesday, September 24th. Four equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $9.60.

Insider Activity at PepGen

In other PepGen news, major shareholder Science Enterprises Plc Oxford purchased 200,000 shares of PepGen stock in a transaction dated Tuesday, September 30th. The stock was acquired at an average cost of $3.20 per share, with a total value of $640,000.00. Following the acquisition, the insider directly owned 4,955,388 shares of the company’s stock, valued at $15,857,241.60. This represents a 4.21% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.20% of the stock is owned by corporate insiders.

Institutional Trading of PepGen

Hedge funds have recently modified their holdings of the business. Rangeley Capital LLC lifted its holdings in shares of PepGen by 133.3% in the 2nd quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock valued at $39,000 after buying an additional 20,000 shares during the period. Marshall Wace LLP acquired a new stake in shares of PepGen in the 2nd quarter valued at approximately $44,000. Qube Research & Technologies Ltd acquired a new stake in shares of PepGen in the 2nd quarter valued at approximately $81,000. AQR Capital Management LLC acquired a new stake in shares of PepGen in the 1st quarter valued at approximately $122,000. Finally, Bridgeway Capital Management LLC lifted its holdings in shares of PepGen by 61.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 91,923 shares of the company’s stock valued at $102,000 after buying an additional 35,000 shares during the period. 58.01% of the stock is owned by institutional investors and hedge funds.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.